All In MedTech

FDA Clearance Tracker · DEN240035

ConcizuTrace™ ELISA

A De Novo grant creates a new device type for a low to moderate risk device with nothing on the market to compare it to. Later devices of this type can use it as their comparison in a 510(k).

Last checked: Nov 20, 2026Latest source record: May 22, 2025 (this decision)Source: openFDAMethods & limitations

De NovoNew device typeBreakthrough

Decided

May 22, 2025

De Novo granted

Time to decision

325 days

Received Jul 1, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

De Novo

Direct

Device class

Class II

The decision

FDA number
DEN240035
Device name
ConcizuTrace™ ELISA
Applicant location
Crumlin, GB
Received
Jul 1, 2024
Decided
May 22, 2025
Decision
De Novo granted
Submission type
Direct

Device type

Device class
Class II
Regulation
21 CFR 864.7298

Every decision under product code SES

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • FDA granted this as a De Novo request, which means it created a new device type. There was no existing device to compare it to.
  • It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).

Source documents

Other decisions for Randox Laboratories, Ltd.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

3 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.